Findings of Scientific Misconduct, 57337-57338 [E7-19850]
Download as PDF
<![CDATA[
57337
Federal Register / Vol. 72, No. 194 / Tuesday, October 9, 2007 / Notices
based providers, enhance biomedical
informatics services, and increase
behavioral and population-based
research resources; and
8. Provide a report of the initial
practice locations of MMC medical and
dental graduates for each of the past 10
years and the number of students
completing their education during the
project period that were assisted by this
program.
Dated: October 2, 2007.
Mirtha R. Beadle,
Deputy Director, Office of Minority Health.
[FR Doc. E7–19737 Filed 10–5–07; 8:45 am]
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Announcement of Anticipated
Availability of Funds for Family
Planning Services Grants
Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science,
Office of Population Affairs.
ACTION: Notice; correction.
AGENCY:
SUMMARY: The Office of Population
Affairs, OPHS, HHS published a notice
in the Federal Register of Monday, June
11, 2007 announcing the anticipated
availability of funds for family planning
services grants. On July 13, 2007, the
Notice was corrected to reflect the
availability of Arizona, Navajo Nation
for competition. Since that time, an
additional State/population/area to be
served has become available for
competition. This Notice reflects the
availability of Illinois, Chicago area for
competition.
FOR FURTHER INFORMATION CONTACT:
Susan B. Moskosky, 240–453–2888.
Correction
In the Federal Register of June 11,
2007, FR Doc. 07–11183, on page 32113,
correct Table I to read:
TABLE I
Approximate
funding
available
States/populations/areas to be served
mstockstill on PROD1PC66 with NOTICES
Region I: No service areas competitive in FY 2008.
Region II:
New York, New York City area ............................................................................................
New Jersey ...........................................................................................................................
Region III:
Maryland ...............................................................................................................................
Southeast Pennsylvania .......................................................................................................
West Virginia ........................................................................................................................
Region IV:
Kentucky ...............................................................................................................................
South Carolina ......................................................................................................................
Florida, Greater Miami area .................................................................................................
Region V:
Illinois, Chicago area ............................................................................................................
Ohio, Central area ................................................................................................................
Minnesota .............................................................................................................................
Region VI:
Arkansas ...............................................................................................................................
Louisiana ..............................................................................................................................
New Mexico ..........................................................................................................................
Region VII:
Iowa ......................................................................................................................................
Iowa ......................................................................................................................................
Region VIII:
Montana ................................................................................................................................
Region IX:
Arizona ..................................................................................................................................
Arizona, Navajo Nation .........................................................................................................
California ...............................................................................................................................
California, Los Angeles area ................................................................................................
Republic of the Marshall Islands ..........................................................................................
Region X:
Alaska ...................................................................................................................................
In addition, on page 32111, in the first
column, under II. AWARD
INFORMATION, please correct the
second sentence to read, ‘‘Of this
amount, OPA intends to make available
approximately $81.9 million for
competing Title X family planning
services grant awards in 23 states,
populations, and/or areas.’’
Application
due date
Approx. grant
funding date
$4,209,000
8,586,000
03/01/08
09/01/07
07/01/08
01/01/08
3,957,000
4,889,000
2,169,000
12/01/07
03/01/08
12/01/07
04/01/08
07/01/08
04/01/08
5,442,500
5,767,000
544,000
03/01/08
03/01/08
06/01/08
07/01/08
07/01/08
09/30/08
205,000
709,500
2,632,500
06/01/08
11/01/07
09/01/07
09/30/08
03/01/08
01/01/08
3,341,000
4,370,000
2,835,000
11/01/07
03/01/08
09/01/07
03/01/08
07/01/08
01/01/08
2,531,500
1,061,500
03/01/08
06/01/08
07/01/08
09/30/08
1,970,000
03/01/08
07/01/08
4,080,500
658,900
20,451,500
472,000
190,500
09/01/07
03/01/08
09/01/07
09/01/07
03/01/08
01/01/08
07/01/08
01/01/08
01/01/08
07/01/08
873,000
03/01/08
07/01/08
Dated: October 2, 2007.
Evelyn M. Kappeler,
Acting Director, Office of Population Affairs.
[FR Doc. E7–19738 Filed 10–5–07; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4150–34–P
Findings of Scientific Misconduct
Office of the Secretary
AGENCY:
ACTION:
Office of the Secretary, HHS.
Notice.
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
VerDate Aug<31>2005
17:07 Oct 05, 2007
Jkt 214001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
E:\FR\FM\09OCN1.SGM
09OCN1
mstockstill on PROD1PC66 with NOTICES
57338
Federal Register / Vol. 72, No. 194 / Tuesday, October 9, 2007 / Notices
have taken final action in the following
case:
Jon Sudb<, D.D.S., Norwegian Radium
Hospital: Based on the findings of an
investigation conducted by the
Investigation Commission appointed by
Norwegian Radium Hospital (NRH) and
the University of Oslo, the respondent’s
own admission, and additional analysis
and information obtained by the Office
of Research Integrity (ORI) during its
oversight review, the U.S. Public Health
Service (PHS) found that Jon Sudb<,
D.D.S., former doctoral student and
faculty member, University of Oslo, and
former physician in the Department of
Medical Oncology and Radiotherapy,
NRH, engaged in scientific misconduct
by reporting fabricated and/or falsified
research in grant application 1 P01
CA106451–01 submitted to the National
Cancer Institute (NCI), National
Institutes of Health (NIH), and its firstyear progress report.
Specifically, PHS found that Dr.
Sudb< engaged in scientific misconduct
by falsifying and fabricating research
that served as the rationale for Project 1,
‘‘Oral Cancer Prevention with Molecular
Targeting Therapy,’’ with Dr. Jon Sudb<,
as project leader, in the grant
application, and by falsifying a progress
report for the awarded grant. In
particular, in Figure 1 of the
Background and Significance section of
the grant application, Dr. Sudb<
reported fabricated/falsified results for
the effects of lesion ploidy upon
survival in patients with oral premalignant lesions. In the Preliminary
Data section of the grant application, Dr.
Sudb< reported several events intended
to demonstrate his experience in the
research field that the Investigation
Commission stated ‘‘appear as pure
fiction.’’ Also, in the first yearly
progress report for the funded grant, Dr.
Sudb< falsified the number of patients
that had been screened for admission to
the study.
In addition to three publications for
which Dr. Sudb< admitted falsifying
and/or fabricating data, the Investigation
Commission found at least twelve other
publications that warranted retraction
because they could not be considered
valid. The research reported in these
publications was not supported by PHS
funds. However, the publications
address the same general research area
as that addressed in the grant
application and demonstrate a pervasive
pattern of falsification/fabrication in
research reporting on the part of Dr.
Sudb<. The falsified/fabricated data
presented in the grant application
purport to demonstrate the feasibility of
VerDate Aug<31>2005
17:07 Oct 05, 2007
Jkt 214001
preventing cancer in a high risk
population with nontoxic oral agents.
Dr. Sudb< has entered into a
Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily
agreed, beginning on August 31, 2007:
(1) To exclude himself permanently
from any contracting or subcontracting
with any agency of the United States
Government and from eligibility or
involvement in nonprocurement
programs of the United States
Government as delineated in the OMB
Guidelines to Agencies on
Governmentwide Debarment and
Suspension at 2 CFR Part 376, et seq.;
Dr. Sudb< agrees that he will not
petition HHS to reverse or reduce the
scope of the permanent voluntary
exclusion or other administrative
actions that are the subject of this
Agreement; and
(2) To exclude himself permanently
from serving in any advisory capacity to
PHS, including but not limited to
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant or contractor to PHS.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John E. Dahlberg,
Acting Director, Office of Research Integrity.
[FR Doc. E7–19850 Filed 10–5–07; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–08–07AM]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
Proposed Project
Study to Examine Web-Based
Administration of the Youth Risk
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Behavior Survey—New—National
Center for Chronic Disease Prevention
and Health Promotion (NCCDPHP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Youth Risk Behavior Survey
(YRBS) has been conducted biennially
since 1991 using paper-and-pencil
questionnaires in schools. Because of
technological improvements in survey
research methods, CDC is considering
changing to web-based administration of
the YRBS. Because YRBS is the only
national source of data for at least 10
national health objectives in Healthy
People 2010, it is critical to understand
(1) Whether it is feasible to change to
web-based administration, and (2) how
a change to web-based administration,
both with and without the use of skip
patterns in the questionnaire, might
affect prevalence estimates of the
priority health risk behaviors reported
in the YRBS.
CDC is proposing an information
collection to address these issues. The
first data collection will be a
questionnaire administered to
approximately 600 U.S. high school
principals to assess perceptions of the
feasibility and acceptability of using
web-based data collection methods for
student surveys and assessments. The
second data collection will be a
questionnaire similar to the YRBS
questionnaire administered to a
convenience sample of 9th and 10th
grade students attending schools in the
United States. Respondents for the
student data collection include students
(n=6,000) who receive instructions for
and complete the student questionnaire,
school administrators (n=80) who
provide information in the School
Recruitment Script for the student
questionnaire, and teachers (n=320)
who complete the Data Collection
Checklist for the student questionnaire.
In the student data collection, students
will be assigned randomly to one of four
conditions: (1) Paper-and-pencil
questionnaire in regular classroom, (2)
web-based questionnaire in computer
lab without programmed skip patterns,
(3) web-based questionnaire in
computer lab with programmed skip
patterns, and (4) web-based
questionnaire without programmed skip
patterns completed at any computer of
the student’s choosing.
There are no costs to respondents
except their time to participate in the
survey and, in the case of school
contacts and teachers, to assist in school
recruitment. The estimated annualized
burden hours are 4,813.
E:\FR\FM\09OCN1.SGM
09OCN1
]]>Agencies
[Federal Register Volume 72, Number 194 (Tuesday, October 9, 2007)]
[Notices]
[Pages 57337-57338]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-19850]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health
[[Page 57338]]
have taken final action in the following case:
Jon Sudb[oslash], D.D.S., Norwegian Radium Hospital: Based on the
findings of an investigation conducted by the Investigation Commission
appointed by Norwegian Radium Hospital (NRH) and the University of
Oslo, the respondent's own admission, and additional analysis and
information obtained by the Office of Research Integrity (ORI) during
its oversight review, the U.S. Public Health Service (PHS) found that
Jon Sudb[oslash], D.D.S., former doctoral student and faculty member,
University of Oslo, and former physician in the Department of Medical
Oncology and Radiotherapy, NRH, engaged in scientific misconduct by
reporting fabricated and/or falsified research in grant application 1
P01 CA106451-01 submitted to the National Cancer Institute (NCI),
National Institutes of Health (NIH), and its first-year progress
report.
Specifically, PHS found that Dr. Sudb[oslash] engaged in scientific
misconduct by falsifying and fabricating research that served as the
rationale for Project 1, ``Oral Cancer Prevention with Molecular
Targeting Therapy,'' with Dr. Jon Sudb[oslash], as project leader, in
the grant application, and by falsifying a progress report for the
awarded grant. In particular, in Figure 1 of the Background and
Significance section of the grant application, Dr. Sudb[oslash]
reported fabricated/falsified results for the effects of lesion ploidy
upon survival in patients with oral pre-malignant lesions. In the
Preliminary Data section of the grant application, Dr. Sudb[oslash]
reported several events intended to demonstrate his experience in the
research field that the Investigation Commission stated ``appear as
pure fiction.'' Also, in the first yearly progress report for the
funded grant, Dr. Sudb[oslash] falsified the number of patients that
had been screened for admission to the study.
In addition to three publications for which Dr. Sudb[oslash]
admitted falsifying and/or fabricating data, the Investigation
Commission found at least twelve other publications that warranted
retraction because they could not be considered valid. The research
reported in these publications was not supported by PHS funds. However,
the publications address the same general research area as that
addressed in the grant application and demonstrate a pervasive pattern
of falsification/fabrication in research reporting on the part of Dr.
Sudb[oslash]. The falsified/fabricated data presented in the grant
application purport to demonstrate the feasibility of preventing cancer
in a high risk population with nontoxic oral agents.
Dr. Sudb[oslash] has entered into a Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily agreed, beginning on August 31,
2007:
(1) To exclude himself permanently from any contracting or
subcontracting with any agency of the United States Government and from
eligibility or involvement in nonprocurement programs of the United
States Government as delineated in the OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension at 2 CFR Part 376, et seq.; Dr.
Sudb[oslash] agrees that he will not petition HHS to reverse or reduce
the scope of the permanent voluntary exclusion or other administrative
actions that are the subject of this Agreement; and
(2) To exclude himself permanently from serving in any advisory
capacity to PHS, including but not limited to service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant or contractor to PHS.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John E. Dahlberg,
Acting Director, Office of Research Integrity.
[FR Doc. E7-19850 Filed 10-5-07; 8:45 am]
BILLING CODE 4150-31-P
